{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-oral/prescribing-information/antivirals/","result":{"pageContext":{"chapter":{"id":"1c9aa8fa-0094-5e8d-9745-40f1deb0a4bd","slug":"antivirals","fullItemName":"Antivirals","depth":2,"htmlHeader":"<!-- begin field 18765d6d-d83b-462e-b6be-c965dcddc112 --><h2>Antivirals</h2><!-- end field 18765d6d-d83b-462e-b6be-c965dcddc112 -->","summary":"","htmlStringContent":"<!-- begin item c4022a64-bac0-4271-a305-7bd64af97c5c --><!-- end item c4022a64-bac0-4271-a305-7bd64af97c5c -->","topic":{"id":"ba62b1ab-ffea-5bce-8fd6-6127df66395a","topicId":"dc5a4c25-cbc0-4da8-9263-892c0ddb29be","topicName":"Palliative care - oral","slug":"palliative-care-oral","lastRevised":"Last revised in October 2018","chapters":[{"id":"92b78ff5-a7a3-533b-9fad-3812221a3e70","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e63cc0ed-d679-5b57-bd5d-a0fffc2bb1c5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0d446cc8-8026-59f2-8be3-a3df05f54690","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94667ccb-b451-5743-aeb8-44fbce6caf13","slug":"changes","fullItemName":"Changes"},{"id":"d267c387-0c44-5636-b186-efd35314ddb7","slug":"update","fullItemName":"Update"}]},{"id":"b1959eca-8652-570a-bf43-e03f35359c72","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"190545c6-de91-566d-97ca-ec507ec5ffd5","slug":"goals","fullItemName":"Goals"},{"id":"51115a15-fe56-57ee-99b3-cdd5c4f1c6a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4d5ef3b4-1232-5943-8fad-b29aa5998488","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"80c55ca1-b9c4-5b9f-9bc7-c6c5fd42df42","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"909bc973-bd01-5f89-8719-11278e3eec78","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"6f3efef7-3ed5-5013-9a70-606c9dbe0943","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"78d7fe5a-a1b6-58ed-9302-ad88f95d8db5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f6c72ae5-a1db-5d81-b680-40d5e677f0e7","slug":"causes","fullItemName":"Causes"},{"id":"c6626f56-2d11-59eb-aaa1-7df1a7759a57","slug":"oral-problems","fullItemName":"Oral problems"},{"id":"047eef6e-58db-5c3e-bbc9-a5b23171e78a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"efa65b1a-1a58-5453-b232-dcb7a4ad4533","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"87dda915-3779-5f4a-afd9-f77577bf772b","slug":"complications","fullItemName":"Complications"}]},{"id":"8d836099-7e31-5881-bb05-20f08d446d0b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b391498b-1e1b-5dcb-a663-5c2acc77475b","slug":"history","fullItemName":"History"},{"id":"b7bc660c-5027-59c4-b81e-daabd0aae4ef","slug":"examination","fullItemName":"Examination"},{"id":"01753f6e-7f5f-5eea-a4f5-860d02375047","slug":"investigations","fullItemName":"Investigations"}]},{"id":"b7921f28-c4d4-513c-9424-c072661841bd","fullItemName":"Management","slug":"management","subChapters":[{"id":"8e4de9d8-84d5-5ccb-a53b-b45928ebc3e0","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"b1f750e8-79b4-5942-abd9-85bc539f3606","slug":"prevention","fullItemName":"Scenario: Prevention"},{"id":"1fcf7fd1-2915-57d3-b741-40d617974983","slug":"dry-mouth","fullItemName":"Scenario: Dry mouth"},{"id":"89366510-b0a8-56fc-bf18-765bf712040e","slug":"oral-pain","fullItemName":"Scenario: Oral pain"},{"id":"dcda2b7f-7a28-5b54-81d7-74ca0a1293ac","slug":"oral-candida-infection","fullItemName":"Scenario: Oral candida infection"},{"id":"ceee9eeb-7174-5047-ae7d-904f58b5e2df","slug":"mouth-ulcers-mucositis","fullItemName":"Scenario: Mouth ulcers and mucositis"},{"id":"ceebbe2f-4f2d-5b69-8484-69a7b63d4155","slug":"halitosis-excessive-salivation-altered-taste","fullItemName":"Scenario: Halitosis, excessive salivation and altered taste"},{"id":"ae4a6023-826b-5bf3-8610-183b69c705c0","slug":"end-of-life-care","fullItemName":"Scenario: End of life care"}]},{"id":"f953784c-8686-5a90-92cd-60d68dbd6845","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"26f08b6c-5b56-5782-8732-efb4b6e713af","slug":"topical-artificial-saliva-saliva-stimulant-products","fullItemName":"Topical artificial saliva and saliva stimulant products"},{"id":"96912fd4-a2b4-50f9-86ed-8bb2e45463c5","slug":"oral-pilocarpine","fullItemName":"Oral pilocarpine"},{"id":"c8127148-af88-5ea4-860a-50fcf5aac054","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"fff90e93-10dd-553e-82f8-0dfd41609a37","slug":"oral-antifungals","fullItemName":"Oral antifungals"},{"id":"065c7442-bd39-51f9-a981-cdaccb1ba40c","slug":"chlorhexidine","fullItemName":"Chlorhexidine"},{"id":"94720495-b83a-5896-aad4-6fe5a74a5f78","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"1c9aa8fa-0094-5e8d-9745-40f1deb0a4bd","slug":"antivirals","fullItemName":"Antivirals"},{"id":"ccf55d3d-9d86-5178-b7de-efe3554f8ad1","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"e8b50dff-617d-541c-8f6c-32d1cc172ad5","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"49c2337d-75af-5e94-a422-dce3f68c22c5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"87ab81b8-3331-56e9-97da-8ccde09bb168","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"fcdbc4c2-0265-55de-83ef-890d4a2eb6e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2d5e11b2-f829-5c8a-ba4e-4bd0c552209e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a6cc052-004c-5f0c-83f8-f04899c06292","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e1ee9217-75fd-57a2-8e67-0f9c468e36c9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a6d40f6b-b733-5a56-8b81-ff55062d9bcb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f953784c-8686-5a90-92cd-60d68dbd6845","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"031bf54b-c203-5366-9543-b39ccf3f11f5","slug":"recommended-antivirals","fullItemName":"Recommended antivirals","depth":3,"htmlHeader":"<!-- begin field eaa49e54-bb83-4a42-a24e-25939acaa491 --><h3>Recommended antivirals</h3><!-- end field eaa49e54-bb83-4a42-a24e-25939acaa491 -->","summary":"","htmlStringContent":"<!-- begin item 88719fec-5b28-4cbd-b2e3-5d4f408571b6 --><!-- begin field 42419637-d83c-405a-8c53-8af9aabd6248 --><ul><li>Topical aciclovir and topical penciclovir are recommended in immunocompetent people who are in the early stages of an uncomplicated herpes simplex infection in the locality of the lips.</li><li>Oral aciclovir is recommended in:<ul><li>Immunocompetent people who are in the early stages of an intraoral herpes infection.</li><li>All immunocompromised people whether herpes simplex infection is in the locality of the lips, or in the mouth.</li></ul></li><li>Topical antiviral preparations are not recommended for treatment of intraoral herpes infection as they are difficult to apply, they may be irritant, and oral antivirals are more effective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-oral/references/\">Worrall, 2009</a>].</li><li>Oral antivirals are not usually needed in managing uncomplicated herpes simplex infection. There is limited evidence that oral aciclovir or valaciclovir can reduce the duration of symptoms by about one day if taken early in the attack (that is, at prodrome) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-oral/references/\">Jensen et al, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-oral/references/\">Worrall, 2009</a>]. Any effect on the duration of pain is very small [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-oral/references/\">Spruance et al, 1990</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-oral/references/\">Rooney et al, 1993</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-oral/references/\">Whitley et al, 1998</a>].<ul><li><strong>Famciclovir </strong>is not licensed for the treatment of oral herpes simplex.</li><li><strong>Inosine pranobex </strong>tablets are licensed for the treatment of mucocutaneous herpes simplex, but there is little evidence of symptom relief or reduction in time to healing in immunocompetent people.</li></ul></li></ul><!-- end field 42419637-d83c-405a-8c53-8af9aabd6248 --><!-- end item 88719fec-5b28-4cbd-b2e3-5d4f408571b6 -->","subChapters":[]},{"id":"adcf58f1-b604-5198-b6dd-00a0573f97c4","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field cc0d7afd-be27-4ed9-aff8-d91ea5e2495f --><h3>Adverse effects</h3><!-- end field cc0d7afd-be27-4ed9-aff8-d91ea5e2495f -->","summary":"","htmlStringContent":"<!-- begin item fd9276d2-2e0a-455d-99ed-2669ec56e64b --><!-- begin field db4de4a2-c128-4170-b348-3dda9d5fc167 --><ul><li><strong>Topical aciclovir and penciclovir </strong>may cause transient stinging, burning, itchiness and numbing of the skin.</li><li><strong>Oral aciclovir is generally well tolerated. </strong>Gastrointestinal adverse effects (for example nausea, vomiting, diarrhoea, and abdominal pain) and skin rashes (including photosensitivity and urticaria) are the most common adverse effects.</li></ul><!-- end field db4de4a2-c128-4170-b348-3dda9d5fc167 --><!-- end item fd9276d2-2e0a-455d-99ed-2669ec56e64b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}